175 related articles for article (PubMed ID: 24041742)
1. STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity.
Indorato RL; DeBonis S; Kozielski F; Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2013 Nov; 86(10):1441-51. PubMed ID: 24041742
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines.
Tcherniuk S; van Lis R; Kozielski F; Skoufias DA
Biochem Pharmacol; 2010 Mar; 79(6):864-72. PubMed ID: 19896928
[TBL] [Abstract][Full Text] [Related]
3. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F
J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877
[TBL] [Abstract][Full Text] [Related]
4. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.
Brier S; Lemaire D; Debonis S; Forest E; Kozielski F
Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401
[TBL] [Abstract][Full Text] [Related]
5. Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation.
Sun L; Sun X; Xie S; Yu H; Zhong D
Biochem Biophys Res Commun; 2014 May; 447(3):465-70. PubMed ID: 24732354
[TBL] [Abstract][Full Text] [Related]
6. Terpendole E and its derivative inhibit STLC- and GSK-1-resistant Eg5.
Tarui Y; Chinen T; Nagumo Y; Motoyama T; Hayashi T; Hirota H; Muroi M; Ishii Y; Kondo H; Osada H; Usui T
Chembiochem; 2014 May; 15(7):934-8. PubMed ID: 24648249
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition.
Wiltshire C; Singh BL; Stockley J; Fleming J; Doyle B; Barnetson R; Robson CN; Kozielski F; Leung HY
Mol Cancer Ther; 2010 Jun; 9(6):1730-9. PubMed ID: 20515952
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.
Debonis S; Skoufias DA; Indorato RL; Liger F; Marquet B; Laggner C; Joseph B; Kozielski F
J Med Chem; 2008 Mar; 51(5):1115-25. PubMed ID: 18266314
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.
Kaan HY; Weiss J; Menger D; Ulaganathan V; Tkocz K; Laggner C; Popowycz F; Joseph B; Kozielski F
J Med Chem; 2011 Mar; 54(6):1576-86. PubMed ID: 21344920
[TBL] [Abstract][Full Text] [Related]
10. Doing the methylene shuffle--further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine.
Abualhasan MN; Good JA; Wittayanarakul K; Anthony NG; Berretta G; Rath O; Kozielski F; Sutcliffe OB; Mackay SP
Eur J Med Chem; 2012 Aug; 54():483-98. PubMed ID: 22749640
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance dependent on allostery: A P-loop rigor Eg5 mutant exhibits resistance to allosteric inhibition by STLC.
Indorato RL; DeBonis S; Garcia-Saez I; Skoufias DA
Front Oncol; 2022; 12():965455. PubMed ID: 36313676
[TBL] [Abstract][Full Text] [Related]
12. An allosteric transition trapped in an intermediate state of a new kinesin-inhibitor complex.
Kaan HY; Ulaganathan V; Hackney DD; Kozielski F
Biochem J; 2009 Dec; 425(1):55-60. PubMed ID: 19793049
[TBL] [Abstract][Full Text] [Related]
13. Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5-Inhibitor Complexes.
Indorato RL; Talapatra SK; Lin F; Haider S; Mackay SP; Kozielski F; Skoufias DA
Mol Cancer Ther; 2019 Dec; 18(12):2394-2406. PubMed ID: 31488701
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
Kaan HY; Ulaganathan V; Rath O; Prokopcová H; Dallinger D; Kappe CO; Kozielski F
J Med Chem; 2010 Aug; 53(15):5676-83. PubMed ID: 20597485
[TBL] [Abstract][Full Text] [Related]
15. Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein.
Sheth PR; Basso A; Duca JS; Lesburg CA; Ogas P; Gray K; Nale L; Mannarino AF; Prongay AJ; Le HV
Biochemistry; 2009 Nov; 48(46):11045-55. PubMed ID: 19824700
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors.
Talapatra SK; Tham CL; Guglielmi P; Cirilli R; Chandrasekaran B; Karpoormath R; Carradori S; Kozielski F
Eur J Med Chem; 2018 Aug; 156():641-651. PubMed ID: 30031975
[TBL] [Abstract][Full Text] [Related]
17. Proteome analysis of apoptosis signaling by S-trityl-L-cysteine, a potent reversible inhibitor of human mitotic kinesin Eg5.
Kozielski F; Skoufias DA; Indorato RL; Saoudi Y; Jungblut PR; Hustoft HK; Strozynski M; Thiede B
Proteomics; 2008 Jan; 8(2):289-300. PubMed ID: 18186019
[TBL] [Abstract][Full Text] [Related]
18. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities.
DeBonis S; Skoufias DA; Lebeau L; Lopez R; Robin G; Margolis RL; Wade RH; Kozielski F
Mol Cancer Ther; 2004 Sep; 3(9):1079-90. PubMed ID: 15367702
[TBL] [Abstract][Full Text] [Related]
19. S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression.
Skoufias DA; DeBonis S; Saoudi Y; Lebeau L; Crevel I; Cross R; Wade RH; Hackney D; Kozielski F
J Biol Chem; 2006 Jun; 281(26):17559-69. PubMed ID: 16507573
[TBL] [Abstract][Full Text] [Related]
20. Photocontrol of mitotic kinesin Eg5 facilitated by thiol-reactive photochromic molecules incorporated into the loop L5 functional loop.
Ishikawa K; Tamura Y; Maruta S
J Biochem; 2014 Mar; 155(3):195-206. PubMed ID: 24334276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
